The injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
Adenosine features the company’s PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Sagent chief executive officer and chairman of the Board Jeffrey Yordon said, "We are pleased to be working with our joint venture partner, Agila, a Mylan company, to support the launch of Adenosine at market formation."
According to IMS, for the 12 months ending January 2014, the US market for Adenosine Injection, USP was about $43m.
Sagent is mainly focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
The company has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and new drug delivery technologies, which result in an extensive and rapidly expanding pharmaceutical product portfolio that fulfils the evolving needs of patients.